In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gynesonics brings in $75mm in late-stage funding

Executive Summary

Gynesonics Inc. (minimally invasive devices for women's health) closed a $75mm late-stage equity round led by Bain Capital Life Sciences (added a board member), which was joined by returning investors, including Abingworth, Advanced Technology Ventures, Endeavour Vision, HealthCrest, InterWest Partners, HBM Partners, Correlation Ventures, and Hercules Technology Growth Capital. The company will use the funds to support launch and commercialization activities for its Sonata (sonography-guided intrauterine imaging and transcervical radiofrequency ablation system for symptomatic uterine fibroids), which is both CE Marked (June 2014) and 510(k) cleared (August 2018). Gynesonics will also put some of the proceeds toward further development of the Sonata platform and clinical research initiatives for reimbursement and market development purposes.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Diagnostic Imaging Equipment & Supplies
      • Ultrasound
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies